Pfizer joins transparency push, posts grants online

Share this article:
Pfizer followed Eli Lilly's lead in posting a list of $10 million in grants and charitable contributions the company made to US medical, scientific and patient organizations during the first quarter of 2008 as “part of an ongoing drive throughout the company to increase transparency.”

The disclosures include medical education grants, fellowship and scholarship support for institutions, grants to patient organizations, medical and scientific associations and academic or other medical centers and charitable contributions.

The largest of the items posted at pfizer.com/transparencyingrants was a grant of $3.4 million to the California Academy of Family Physicians for a three-year national professional education campaign around smoking cessation. Pfizer markets Chantix for smoking cessation. Other grants included $500,000 to Family Health International for malaria patient education and treatment and $237,500 to the Massachusetts Institute of Technology for its clinical investigator training program with Beth Israel Deaconess Medical Center.

As with Lilly's, the site will be updated quarterly.

Pfizer began disclosing political contributions and registering clinical trials with clinicaltrials.gov in 2002. In 2004, the company began publicly posting clinical trial results at clinicalstudyresults.org. In 2006 Pfizer launched a regularly updated public site describing compounds under development and their progress, and in 2007, Pfizer began reporting FDA post-marketing commitments relating to safety, efficacy or the use of medicines.  
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...